OncoRedox develops a testing device that detects cancer through urine samples by utilizing biochemical electrodes to analyze redox metabolic signatures. This technology enables early cancer detection, providing doctors with critical information for timely intervention.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for cancer detection often involve invasive procedures or expensive imaging techniques, leading to delays in diagnosis and increased patient anxiety. The need for frequent monitoring, especially for individuals at high risk or those undergoing treatment, further exacerbates these challenges.
Solution
OncoRedox is developing a non-invasive cancer detection system that analyzes urine samples using electrochemical sensors to identify redox metabolic signatures associated with malignancy. The technology aims to provide a rapid, cost-effective, and convenient method for early cancer screening and monitoring. By detecting subtle changes in redox activity, the device offers the potential for earlier diagnosis, enabling timely intervention and improved patient outcomes. The system is designed to be easily integrated into routine checkups, facilitating frequent and accessible cancer monitoring.
Target Audience
The primary target audience includes healthcare providers, oncologists, and individuals at high risk for cancer, as well as those undergoing cancer treatment.
Features
- Electrochemical sensors for detecting redox metabolic signatures in urine samples
- Non-invasive and convenient sample collection
- Rapid analysis and result generation
- Potential for early cancer detection and monitoring
- Cost-effective screening solution